secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001193125-22-278606
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris acquires Oyster Point Pharma and Famy Life Sciences for $700-750M to create ophthalmology franchise
--------------------------------------------------------------------------------

- Aggregate purchase price $700-750M cash; Oyster Point at $11/share upfront plus up to $2 CVR; expects Q1 2023 close.
- Sees combined ops adding at least $1B net sales and $500M adj. EBITDA by 2028; expects acquisitions to be adjusted EPS accretive in 2023.
- Reaffirms total pre-tax proceeds from Biocon Biologics and non-core asset divestitures up to ~$9B; plans $1B stock repurchase program in 2023.
- Provides 2024-2028 financial targets: total revenue CAGR ~3%, adj. EBITDA CAGR ~4-5%, adj. EPS CAGR ~mid-teens.
- Ophthalmology division to be led by current Oyster Point CEO Jeff Nau upon closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/0001193125-22-278606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/d496725d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-278606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer